Here are the S-3 shelf registrations from Zura Bio Limited (ZURA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow ZURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZURA filings page.
Zura Bio Limited may offer and sell up to $114,044,900 of Class A Ordinary Shares through an at-the-market offering under its amended sales agreement with Leerink Partners, after the registration statement becomes effective. The remaining capacity reflects $10,955,100 of prior sales against a $125,000,000 agreement limit. Leerink Partners will act as sales agent or principal, is not required to sell a specific amount, and earns a 3.0% commission on gross sales price per share.
At the assumed price of $3.56 per share, the prospectus illustrates 32,035,084 shares sold and estimates $1.32 of immediate dilution per share after commissions and estimated offering expenses. The base prospectus allows up to $700,000,000 in aggregate securities, with the ATM shares counted within that amount. Zura intends to use net proceeds for working capital, pipeline advancement and general corporate purposes. Its lead candidate, tibulizumab, is in Phase 2 clinical trials.